20 results
Keyword paclitaxel Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Paxene
paclitaxel, Sarcoma, Kaposi, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Breast Neoplasms
Date of authorisation: 19/07/1999, Revision: 14, Withdrawn, Last updated: 22/03/2010Withdrawn paclitaxel Overview The marketing authorisation … Public statement on Paxene (paclitaxel): Withdrawal of the marketing … Public statement on Paxene (paclitaxel) Withdrawal of the marketing … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel ratiopharm GmbH
clopidogrel, Peripheral Vascular Diseases, Acute Coronary Syndrome, Myocardial Infarction, Stroke
Date of authorisation: 28/07/2009,
, Revision: 12, Withdrawn, Last updated: 25/01/2021
-
List item
Human medicine European public assessment report (EPAR): Onzeald
etirinotecan pegol, Breast Neoplasms
Date of refusal: 08/01/2018, Refused, Last updated: 02/02/2018 -
List item
Human medicine European public assessment report (EPAR): Topotecan Teva
topotecan, Ovarian Neoplasms, Uterine Cervical Neoplasms, Small Cell Lung Carcinoma
Date of authorisation: 21/09/2009,, Revision: 8, Withdrawn, Last updated: 13/07/2018
-
List item
Human medicine European public assessment report (EPAR): Angiox
Bivalirudin, Acute Coronary Syndrome
Date of authorisation: 20/09/2004, Revision: 22, Withdrawn, Last updated: 14/09/2018 -
List item
Human medicine European public assessment report (EPAR): Nivolumab BMS
nivolumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/07/2015, Withdrawn, Last updated: 14/01/2016 -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Acino
clopidogrel, Peripheral Vascular Diseases, Acute Coronary Syndrome, Myocardial Infarction, Stroke
Date of authorisation: 28/07/2009,, Revision: 6, Withdrawn, Last updated: 04/01/2018
-
List item
Human medicine European public assessment report (EPAR): Clopidogrel Teva Pharma (previously Clopidogrel HCS)
clopidogrel (as hydrochloride), Myocardial Infarction, Peripheral Vascular Diseases, Stroke
Date of authorisation: 21/09/2009,, Revision: 9, Withdrawn, Last updated: 24/10/2017
-
List item
Human medicine European public assessment report (EPAR): Repso
leflunomide, Arthritis, Rheumatoid, Arthritis, Psoriatic
Date of authorisation: 14/03/2011,, Revision: 11, Withdrawn, Last updated: 21/04/2016
-
List item
Human medicine European public assessment report (EPAR): Docetaxel Mylan
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms
Date of authorisation: 31/01/2012,, Revision: 6, Withdrawn, Last updated: 12/03/2015
-
List item
Human medicine European public assessment report (EPAR): Docefrez
docetaxel, Stomach Neoplasms, Adenoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms
Date of authorisation: 10/05/2010,, Revision: 1, Withdrawn, Last updated: 14/06/2012
-
List item
Human medicine European public assessment report (EPAR): Capecitabine SUN
capecitabine, Stomach Neoplasms, Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms
Date of authorisation: 21/06/2013,, Revision: 3, Withdrawn, Last updated: 22/12/2016
-
List item
Human medicine European public assessment report (EPAR): Docetaxel Teva Pharma
docetaxel, Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, Prostatic Neoplasms
Date of authorisation: 21/01/2011,, Revision: 6, Withdrawn, Last updated: 21/01/2014
-
List item
Human medicine European public assessment report (EPAR): Adlumiz
anamorelin hydrochloride, Cachexia, Anorexia, Carcinoma, Non-Small-Cell Lung
Date of refusal: 16/11/2017, Refused, Last updated: 30/11/2017 -
List item
Human medicine European public assessment report (EPAR): Istodax
romidepsin, Lymphoma, Non-Hodgkin
Date of refusal: 12/02/2013,
, Refused, Last updated: 14/03/2013
-
List item
Human medicine European public assessment report (EPAR): Folotyn
Pralatrexate, Lymphoma, T-Cell
Date of refusal: 21/06/2012,, Refused, Last updated: 11/07/2012
-
List item
Human medicine European public assessment report (EPAR): Avandia
rosiglitazone, Diabetes Mellitus, Type 2
Date of authorisation: 11/07/2000, Revision: 23, Withdrawn, Last updated: 08/06/2016 -
List item
Human medicine European public assessment report (EPAR): Neupopeg
pegfilgrastim, Neutropenia, Cancer
Date of authorisation: 22/08/2002, Revision: 9, Withdrawn, Last updated: 25/01/2009 -
List item
Human medicine European public assessment report (EPAR): Turalio
Pexidartinib, Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular
Date of refusal: 28/10/2020,
, Refused, Last updated: 18/12/2020
-
List item
Human medicine European public assessment report (EPAR): Ablavar (previously Vasovist)
gadofosveset trisodium, Magnetic Resonance Angiography
Date of authorisation: 03/10/2005, Revision: 10, Withdrawn, Last updated: 14/11/2011